Bone implant developer GreenBone Ortho has secured $9.4m in funding from investors including Helsinn's corporate venturing subsidiary.

Oncology drug startup Repare Therapeutics has emerged from stealth with series A funding from investors including Celgene Switzerland.

Repare Therapeutics was co-founded by researchers from Lunenfeld-Tanenbaum Research Institute, University of Toronto and New York University.

Imprimis Pharmaceuticals spinout Eton Pharmaceuticals has secured $20m in a private placement from a syndicate of unnamed investors.

Baxalta-backed Syntimmune has raised $50m in an Apple Tree Partners-led series B round that will fund clinical development of its autoimmune diseases treatment.

Sleep aid developer Rythm has disclosed $22m of funding from investors including insurance company Maif, about $11m of which it has secured since early 2016.

Gamida Cell has raised new funding from a consortium including Novartis, a shareholder since 2014 when it invested $35m in the cellular therapy developer.

Sanovas has signed an agreement with the government of Suzhou in China to create a $75m fund and innovation centre at the Chinese Academy of Sciences.

The eye disease treatment developer has raised $7.5m in a round co-led by pharmaceutical company Abdi Ibrahim, six months after closing a $6m series A.